Asparaginase-based cancer therapy
The present invention relates to an improved preparation and delivery of asparaginase for use in medicine, e.g. in human and veterinary medicine.
1 . A method for the treatment of leukemia or lymphoma comprising administering a therapeutically effective amount of monomeric asparaginase in urea to a subject in need thereof, wherein the monomeric asparaginase is administered by intravenous infusion.
2 . The method of claim 1 , wherein the monomeric asparaginase is administered to the subject under conditions which promote protein transport into the interstitial fluid.
3 . The method of claim 1 , wherein the monomeric asparaginase is administered to the subject under conditions wherein the subject is provided with concurrent infusion of insulin and glucose, wherein the glucose is infused as needed to maintain a normal level of plasma glucose concentration.
4 . The method of claim 1 , wherein the subject is a human patient.
5 . The method of claim 1 , wherein the subject is an animal patient.
6 . The method of claim 1 , wherein the monomeric asparaginase is administered to a human subject suffering from acute lymphoblastic leukemia, acute myeloid leukemia or non-Hodgkin's lymphoma.
7 . The method of claim 5 , wherein the subject is a cat or a dog.